Clinical categorization of breast cancer into Luminal A, Luminal B, HER2 overexpression, and triple-negative subtypes, based on ER, PR, HER2, and Ki67, has guided therapeutic decisions [4, 5]. This evidence concerns the gene ERBB2 and breast carcinoma.